Background: Fatty acids and lipid mediator signaling play an important role in the
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| INTRODUCTION
Fatty acid levels and their metabolism can have significant effects on immune cell polarization and inflammatory responses. For example, the metabolism of arachidonic acid by cyclooxygenase enzymes leads to the production of prostaglandins, leukotrienes, and other bioactive eicosanoids, which all have significant effects on the immune system. [1] [2] [3] Indeed, in obese individuals, an increase in circulating free fatty acids driven by the metabolic overload has been demonstrated to affect immune cells and chronic inflammatory processes. 4 Certain fatty acids, for example, n-3 polyunsaturated fatty acids (PUFAs) or monounsaturated fatty acids (MUFAs), can potentially decrease inflammation through several mechanisms, while saturated fatty acids (SFAs) may contribute to the magnitude of proinflammatory responses. [5] [6] [7] The balance between pro-and anti-inflammatory fatty acids is increasingly thought to be important in many chronic inflammatory disorders.
It is not only the fatty acid levels themselves that are important, but also the endogenous metabolism of fatty acids, for example, by elongation and desaturation, will influence their effects in the body.
The plasma fatty acid desaturation index (MUFA/SFA ratio) indirectly assesses stearoyl-CoA desaturase (SCD) activity. The SCD enzyme is a rate-limiting enzyme in the synthesis of MUFAs, 8 and SCD mutations were identified as the source of the asebia phenotype in mice. 9 SCD plays an important role in whole-body energy balance. Notably, skin-specific SCD deletion resulted in increased whole-body energy expenditure, protection against diet-induced adiposity, hepatic steatosis, and glucose intolerance, thus linking cutaneous lipid metabolism to whole-body energy balance. 10 SCD has also been implicated in the regulation of adipocyte inflammation, macrophage inflammation, myocyte, and endothelial cell function.
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Impaired fatty acid metabolism has been previously proposed to contribute to the pathogenesis of asthma. [12] [13] [14] One asthma endotype, which frequently presents with more severe clinical features and corticosteroid resistance, is associated with obesity. [15] [16] [17] [18] Weight loss in obese asthmatics can substantially impact asthma symptoms and airway hyper-responsiveness. 19 However, it is likely that metabolic factors, such as free fatty acids, could play a role in the development of asthma in obese and nonobese individuals. In this study, we quantified free fatty acid levels in obese and nonobese asthma patients. Circulating levels of many fatty acids were increased in obese patients, but surprisingly, we found that the desaturation index was significantly lower in nonobese asthma patients, suggesting reduced SCD activity in nonobese asthma patients. Follow-on studies in animal models and primary human bronchial epithelial cells provide additional functional support for the protective role of this enzyme within the lung.
2 | METHODS
| Patient groups
This was an observational study in which 161 volunteers were recruited in four groups-obese asthma (n=40), obese nonasthma (n=40), nonobese asthma (n=41), and nonobese nonasthma healthy controls (n=40 In addition, female C57Bl/6 mice (6-8 weeks) were obtained from Charles River and were sensitized intranasally (i.n.) with 1 lg of house dust mite extract (HDM, Greer Laboratories, Lenoir, NC, USA)
or NaCl on day 0 and challenged with 10 lg of HDM on days 7-11 before they were analyzed at day 14 for isolation of lung tissue and serum extraction. Table S1 , and all were synthesized by Microsynth (Balgach, Switzerland). The relative expression of each gene was normalized according to the DDCT method.
| Bronchial epithelial cell culture
Primary human bronchial epithelial cells were purchased from Lonza (Basel, Switzerland) or were generated from bronchial brushings of asthmatic patients and control subjects, as previously described. Virapur, San Diego, USA). The apical surface was washed twice with PBS and all remaining liquid removed. Epithelial cell viral titer was quantified using a PCRmax qPCR kit for HRV16, according to the manufacturer's instructions. Supernatant IP-10 levels were quantified using a Bio-Plex kit (Bio-Rad, Hercules, USA).
| Statistical analysis
Graphing and statistical analysis were performed using Prism 5
(Graph Pad Software, San Diego, CA, USA). Differences between more than two groups were analyzed for statistical significance using one-way ANOVA followed by post hoc analysis. Differences between two groups were analyzed using the Mann-Whitney U test.
P-values <.05 were considered statistically significant.
3 | RESULTS
| Obesity is associated with elevated circulating levels of fatty acids
Patient demographic and clinical details are included in Table 1 .
Serum levels of the fatty acids myristic acid (tetradecanoic acid, C14:0), pentadecanoic acid (C15:0), and stearic acid (octadecanoic acid, C18:0) were significantly elevated in obese nonasthma patients compared to nonobese nonasthma controls, while a similar nonstatistically significant trend was observed for obese asthma patients compared to nonobese asthma patients (Figure 1 ). Palmitic acid (hexadecanoic acid, C16:0), palmitoleic acid (C16:1), a-linolenic acid (C18:3), and docosahexaenoic acid (C22:6) were significantly elevated in both obese nonasthma and obese asthma patients compared to their respective nonobese controls (Figure 1 ). Serum arachidonic acid (C20:4) levels were significantly higher in obese asthma patients compared to nonobese asthma patients, while no differences were observed between obese and nonobese nonasthma controls ( Figure 1 ). Serum levels of capric acid (decanoic acid C10:0), undecanoic acid (C11:0), and lauric acid (dodecanoic acid, C12:0)
were similar for all groups (Fig. S1 ).
We next determined whether serum fatty acid levels were associated with any of the patient clinical parameters. Interestingly, serum levels of palmitoleic acid, arachidonic acid, and docosahexaenoic acid were significantly reduced in nonobese asthma patients with severe disease (Figure 2A ), which was not observed in obese asthma patients. In addition, the serum desaturation index (palmitoleic:palmitic ratio) was significantly suppressed in nonobese severe asthma patients, with a trend toward reduced levels in mild/moderate nonobese asthma patients, which was not observed in obese | 1747 asthma patients ( Figure 2B ). The serum desaturation index did not correlate with the use or dose of steroids or LABAs (Fig. S2 ).
| SCD activity is suppressed in murine models of allergic airway inflammation
To better understand the relevance of the suppressed desaturation index observed in nonobese asthma patients, we quantified the desaturation index in mice that were sensitized and challenged with ovalbumin. Similar to the observation in humans, the C16:1-to-C16:0 ratio was significantly reduced in the mouse model ( Figure 3A ). To confirm this result, the desaturation index using the C18:1-to-C18:0 ratio was also calculated. The results were identical ( Figure 3B ), suggesting that the metabolism of fatty acids changes following the induction of allergic airway inflammation. The desaturation index reflects the expression and activity of SCD enzymes. Thus, the gene expression of the two major murine SCD isoforms, SCD1 and SCD2, in the murine lung and liver was quantified. SCD1 and SCD2 gene expressions were both significantly decreased in the lungs of ovalbumin-challenged animals ( Figure 3C ,D), while they remained unchanged in the liver (Fig. S3 ). In addition, SCD1 and SCD2 gene expressions were further decreased in the lung following challenge with house dust mite extract ( Figure 3C,D) . These data suggest that the systemic suppression of the desaturation index, which reflects suppressed SCD activity, may be at least partially due to a allergic inflammation-induced decrease in SCD activity within the lung.
As decreased SCD activity correlates with the presence of airway inflammation, both in humans and mice, the functional consequences for the lung following inhibition of SCD activity were determined.
Mice were administered an SCD1 inhibitor, MF-438, for 15 days, and thereafter, airway hyper-responsiveness in response to methacholine challenge was assessed. With increasing doses of F I G U R E 1 Serum fatty acid levels are elevated in obese volunteers. Myristic acid, pentadecanoic acid, palmitic acid, palmitoleic acid, stearic acid, a-linolenic acid, arachidonic acid, and docosahexaenoic acid were measured in serum samples from obese and nonobese asthma and nonasthma subjects. *P<.05; **P<.01
methacholine, MF-438-treated animals displayed significant defects in tissue elasticity and tissue dampening ( Figure 3E,F) . The measurement of tissue elastance reflects the energy conservation in the alveoli, while the tissue dampening measurement is closely related to tissue resistance and reflects the energy dissipation in the alveoli. F I G U R E 3 Stearoyl-coenzyme A desaturase (SCD) expression and activity is downregulated in murine models of airway inflammation. The desaturation index, calculated as palmitoleic/palmitic acid ratio (A) or stearic/oleic acid ratio (B), was suppressed in ovalbumin (OVA)-sensitized and OVA-challenged mice (n=8-10 mice per group). Relative SCD1 (C) and SCD2 (D) gene expressions were reduced in the lungs of OVA-or HDM-challenged animals (at least six mice included per group). Methacholine-induced lung elasticity (E) and dampening (F) are increased in mice treated with the SCD inhibitor MF-438 (n=8 mice per group). *P<.05
Expression of the two human SCD isoforms, SCD1 and SCD5, was significantly lower in epithelial cells from asthma patients compared to healthy volunteers ( Figure 4A,B) . In addition to SCD expression, the gene expression of other enzymes involved in fatty acid metabolism was quantified. Acetyl-CoA carboxylase (ACC) catalyzes the carboxylation of acetyl-CoA to malonyl-CoA, while fatty acid synthase (FAS) catalyzes the synthesis of palmitic (C16:0) from malonyl-CoA.
There was no difference in ACCalpha gene expression, but ACCbeta was significantly upregulated and FAS was significantly downregulated in bronchial epithelial cells from asthma patients (Fig. S4 ).
These data suggest that fatty acid metabolism is significantly disturbed in epithelial cells from asthma patients.
To model the cytokine environment of the asthmatic lung, bron- 
| DISCUSSION
Asthma is characterized by recurrent and reversible airflow obstruction with airway inflammation central to its pathogenesis. 25 However, successful management of patients with asthma continues to be problematic due to the heterogeneity of the disease with different phenotypes and endotypes continuingly being described. 26 In this study, we describe significant differences in circulating fatty acids levels in patients with obese and nonobese asthma. In particular, nonobese patients with severe disease had significantly reduced serum fatty acid levels. In addition, a suppressed MUFA:SFA ratio suggested reduced desaturase activity. Similar to humans, murine models of respiratory allergic inflammation also showed reduced desaturase activity, which correlated with diminished SCD expression in the lung. Inhibition of SCD had negative effects on lung physiology in the mouse and on primary human bronchial epithelial cell responses in vitro.
Our results showing increased serum levels of many different fatty acids in obese individuals are consistent with existing published reports. 27 Similarly, serum fatty acid levels were elevated in obese asthma patients compared to nonobese asthma patients. However, the reduction in MUFA and PUFA serum levels was only observed in nonobese asthma patients with severe disease and not in obese asthma patients with severe disease. This may suggest a different inflammatory process within the lungs of obese vs nonobese asthma patients, associated with altered metabolism of these fatty acids. Alternatively, dietary differences associated with obesity may compensate for the loss of these fatty acids from the circulation in obese patients with severe asthma. Supplementation of nonobese severe asthma patients with MUFAs or PUFAs may help to restore the availability of these important fatty acids. Clinical studies do show a modest improvement in asthma symptoms following fatty acid supplementation, but truly efficacious treatment schedules are still lacking. [28] [29] [30] Further evidence for altered metabolism of fatty acids in nonobese vs obese asthma patients was suggested by the reduced desaturation index in nonobese patients. The SCD enzyme that determines the desaturation index has previously been shown to be important for maintenance of a healthy skin barrier. SCD1-deficient mice exhibit a severe skin phenotype that includes alopecia, atrophy of sebaceous glands, dermatitis, and increased permeability of the skin barrier. 31 These skin defects were associated with a dramatically altered skin lipid profile and reduced the immunological response to effectively protect against skin-associated bacterial infection. is currently available on SCD polymorphisms in asthma. However, a recent genomewide association study of peripheral blood CD4+lym-phocytes did identify a locus within the fatty acid desaturase gene (FADS1/FADS2) on 11q, which was associated with asthma susceptibility. 34 FADS1 and FADS2 encode for D5-and D6-desaturase enzymes, respectively, while SCD is a D9-desaturase. Thus, while these enzymes have different targets, this study also implies that inappropriate fatty acid desaturation may play an important role in the development of inflammation within the airways.
In conclusion, fatty acid desaturase activity is reduced in nonobese asthma patients. The functional importance of this change in enzymatic activity will need to be confirmed and further expanded in future studies, but our observations suggest that fatty acid desaturase activity should be considered an important biological process that contributes to lung inflammatory and immune responses. Significant differences in obese asthmatics compared to nonobese asthmatics continue to be described, further supporting the differential diagnosis and treatment of these asthma endotypes. [35] [36] [37] [38] CONFLI 
